- Home
- SRG vs GNFT Comparison
SRG vs GNFT Comparison
Compare SRG & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- GNFT
- Stock Information
- Founded
- SRG 2014
- GNFT 1999
- Country
- SRG United States
- GNFT France
- Employees
- SRG N/A
- GNFT N/A
- Industry
- SRG Real Estate Investment Trusts
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRG Real Estate
- GNFT Health Care
- Exchange
- SRG Nasdaq
- GNFT Nasdaq
- Market Cap
- SRG 238.6M
- GNFT 189.6M
- IPO Year
- SRG 2015
- GNFT 2019
- Fundamental
- Price
- SRG $4.09
- GNFT $3.80
- Analyst Decision
- SRG
- GNFT Strong Buy
- Analyst Count
- SRG 0
- GNFT 1
- Target Price
- SRG N/A
- GNFT $13.00
- AVG Volume (30 Days)
- SRG 283.5K
- GNFT 9.8K
- Earning Date
- SRG 11-12-2024
- GNFT 09-19-2024
- Dividend Yield
- SRG N/A
- GNFT N/A
- EPS Growth
- SRG N/A
- GNFT N/A
- EPS
- SRG N/A
- GNFT 0.47
- Revenue
- SRG $56,359,000.00
- GNFT $86,225,222.00
- Revenue This Year
- SRG N/A
- GNFT $155.44
- Revenue Next Year
- SRG N/A
- GNFT N/A
- P/E Ratio
- SRG N/A
- GNFT $7.53
- Revenue Growth
- SRG N/A
- GNFT 175.45
- 52 Week Low
- SRG $3.63
- GNFT $3.31
- 52 Week High
- SRG $9.87
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- SRG 40.43
- GNFT 29.24
- Support Level
- SRG $3.97
- GNFT $3.63
- Resistance Level
- SRG $4.55
- GNFT $3.88
- Average True Range (ATR)
- SRG 0.15
- GNFT 0.10
- MACD
- SRG -0.04
- GNFT 0.02
- Stochastic Oscillator
- SRG 19.31
- GNFT 15.30
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.